Advanced molecular technology have the potential of healing future lung cancer patients

By Cai Wenjun | June 30, 2015, Tuesday |

Online Edition

A latest, state-of-the-art molecular testing for lung cancer on one specific gene mutation is now available in the mainland market. This cutting-edge technology can assist doctors by allowing patients to be entitled to more individualized and specific treatments, medical experts told a seminar on genetic testing and lung cancer treatment.

Lung cancer is divided into two types: small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer covers approximately 80 percent of total lung cancer patients.

Treatments for the two types of lung cancers are different.

A part of non-small cell lung cancer patients were discovered to have specific mutation of the anaplastic lymphoma kinase (ALK) fusion gene. These cancer patients are often non smokers and young people.

An ALK testing technology has been introduced to China, as doctors can prescribe targeted medicine for patients with such genetic expression.

In addition, clinical research found that 60 percent of patients with ALK expression can have a positive reaction to targeted medicine, experts stated.

Metro

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Advanced molecular technology have the potential of healing future lung cancer patients

Email this to your friend